Last updated: June 21, 2022
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Not Recruiting
Phase
2/3
Condition
Rash
Atopic Dermatitis
Allergy
Treatment
N/AClinical Study ID
NCT04419584
AD study
Ages 4-17 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age of 4 to 17 (Chinese only);
- With EASI ≥ 10;
- Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematouspapules and plaques; and
- Provide written informed consent form (signed by one of their parents)
Exclusion
Exclusion Criteria:
- History of allergy to Chinese medicines;
- AD with Yang deficiency in syndrome differentiation, such as pale looking, alwaysfeeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such asurinary difficulty, excessive urination or incontinence
- Known overt bacterial infections in the skin;
- Known pregnancy;
- Known severe medical conditions, such as cardiovascular, liver or renal dysfunction orDiabetes Mellitus;
- Having used oral corticosteroids, oral antibiotics, other immunosuppressive or anypreparation of oral herbal medicines for the treatment of AD in the past month;
- Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitisor psoriasis; and
- Has taken anti-coagulant or anti-platelet drugs in the past month.
- Has taken any probiotics, prebiotics in the last month
- Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency
Study Design
Total Participants: 64
Study Start date:
September 10, 2020
Estimated Completion Date:
May 31, 2023
Study Description
Connect with a study center
The Chinese University of Hong Kong
Hong Kong,
Hong KongSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.